$23.520
-4.925 (-20.94%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Cyclerion Therapeutics Inc (CYCN) Moving Averages Convergence Divergence (MACD) indicator is 0.82, suggesting CYCN is Neutral.
Cyclerion Therapeutics Inc (CYCN) 20-Day simple moving average is 28.08, while Cyclerion Therapeutics Inc (CYCN) share price is $—, making it Sell.
Cyclerion Therapeutics Inc (CYCN) 60-Day simple moving average is 25.62, while Cyclerion Therapeutics Inc (CYCN) share price is $—, making it Sell.
Technical Analysis for CYCN
AI Technical CYCNAs of 2026-09-05, the technical board for Cyclerion Therapeutics Inc (CYCN) reads neutral: 5 indicators are flashing buy, 5 are indicating sell, and 3 are neutral. Price at $23.52 sits below the 5-day, 10-day, 20-day and 60-day moving averages and above the 200-day.
Momentum readings: RSI stands at 41.239, MACD stands at 0.818 (Buy), Stochastic %K stands at 50.553, Stochastic %D stands at 68.22 and CCI stands at -225.597 (Buy).
CYCN trades below the 60-day SMA (25.62) and above the 200-day SMA (17.92). Immediate resistance sits at Classic R1 36.71, then R2 44.82. Support sits at Classic S1 20.12, then S2 11.64.
Cyclerion Therapeutics Inc (CYCN) Support & Resistance Level
Cyclerion Therapeutics Inc (CYCN) Technical Indicators
2026-09-05
| Name | Value |
|---|---|
| RSI_14 | 41.239 |
| STOCHk_14_3_3 | 50.553 |
| STOCHd_14_3_3 | 68.220 |
| CCI_20 | -225.597 |
| AO_5_34 | 2.137 |
| MOM_10 | -3.990 |
| MACD_12_26_9 | 0.818 |
Cyclerion Therapeutics Inc (CYCN) Relative Strength Index (RSI_14) is 41.239, creating a Neutral signal.
Cyclerion Therapeutics Inc (CYCN) Stochastic %K is 50.553, creating a Neutral signal.
Cyclerion Therapeutics Inc (CYCN) Stochastic %D is 68.220, creating a Neutral signal.
Cyclerion Therapeutics Inc (CYCN) CCI_20 is -225.597, creating a Buy signal.
Cyclerion Therapeutics Inc (CYCN) Awesome Oscillator (AO) is 2.137, creating a Buy signal.
Cyclerion Therapeutics Inc (CYCN) Momentum (MOM) is -3.990, creating a Sell signal.
Cyclerion Therapeutics Inc (CYCN) Moving Average Convergence Divergence (MACD) is 0.818, creating a Buy signal.
Cyclerion Therapeutics Inc (CYCN) Moving Average
2026-09-05
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 29.764 | Sell |
| MA_10 | 28.609 | Sell |
| MA_20 | 28.080 | Sell |
| MA_60 | 25.618 | Sell |
| MA_200 | 17.923 | Buy |
| MA_250 | 17.365 | Buy |
Cyclerion Therapeutics Inc (CYCN) 5-Day simple moving average is 29.764, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Sell.
Cyclerion Therapeutics Inc (CYCN) 10-Day simple moving average is 28.609, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Sell.
Cyclerion Therapeutics Inc (CYCN) 20-Day simple moving average is 28.080, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Sell.
Cyclerion Therapeutics Inc (CYCN) 60-Day simple moving average is 25.618, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Sell.
Cyclerion Therapeutics Inc (CYCN) 200-Day simple moving average is 17.923, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Buy.
Cyclerion Therapeutics Inc (CYCN) 250-Day simple moving average is 17.365, while Cyclerion Therapeutics Inc (CYCN) share price is $, making it a Buy.
Related articles
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.